Print
Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer
https://www.facingourrisk.org/XRAY/pembrolizumab-for-triple-negative-breast-cancer
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549
The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence. This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Is Keytruda a treatment option for my type of breast cancer?
- If Keytruda is not an option for me now, might it be an option in the future?
- What side effects might I experience with this treatment?
- If I have serious side effects, will I need to stop treatment?
- Are any other drugs available to treat my cancer?
- Should my tumor be genetically tested to see if there are other treatments my cancer may respond to?
Open Clinical Trials
The following are studies enrolling people with early-stage, TNBC.
A number of other clinical trials for patients with early-stage TNBC can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.